Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C.

Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.

PMID:
29258292
2.

Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer.

Hassanzadeh E, Alessandrino F, Olubiyi OI, Glazer DI, Mulkern RV, Fedorov A, Tempany CM, Fennessy FM.

Abdom Radiol (NY). 2018 May;43(5):1237-1244. doi: 10.1007/s00261-017-1297-y.

PMID:
28840280
3.

Cancer Imaging Fellowship Training: Utility and Added Value in the Modern Era.

Krajewski KM, Howard SA, Shinagare AB, Van den Abbeele AD, Fennessy FM.

J Am Coll Radiol. 2017 Oct;14(10):1345-1348. doi: 10.1016/j.jacr.2017.06.005. Epub 2017 Jul 8. No abstract available.

PMID:
28697959
4.

Multiparametric Magnetic Resonance Imaging of the Prostate: Repeatability of Volume and Apparent Diffusion Coefficient Quantification.

Fedorov A, Vangel MG, Tempany CM, Fennessy FM.

Invest Radiol. 2017 Sep;52(9):538-546. doi: 10.1097/RLI.0000000000000382.

5.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

6.

Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.

Gibson WJ, Ruan DT, Paulson VA, Barletta JA, Hanna GJ, Kraft S, Calles A, Nehs MA, Moore FD Jr, Taylor-Weiner A, Wala JA, Zack TI, Lee TC, Fennessy FM, Alexander EK, Thomas T, Janne PA, Garraway LA, Carter SL, Beroukhim R, Lorch JH, Van Allen EM.

Clin Cancer Res. 2017 May 1;23(9):2367-2373. doi: 10.1158/1078-0432.CCR-16-2154-T. Epub 2016 Oct 17.

7.

Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology.

Glazer DI, Hassanzadeh E, Fedorov A, Olubiyi OI, Goldberger SS, Penzkofer T, Flood TA, Masry P, Mulkern RV, Hirsch MS, Tempany CM, Fennessy FM.

Abdom Radiol (NY). 2017 Mar;42(3):918-925. doi: 10.1007/s00261-016-0942-1.

8.

Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review.

Hassanzadeh E, Glazer DI, Dunne RM, Fennessy FM, Harisinghani MG, Tempany CM.

Abdom Radiol (NY). 2017 Jan;42(1):278-289. doi: 10.1007/s00261-016-0871-z. Review.

9.

Characterization of gradient echo signal decays in healthy and cancerous prostate at 3T improves with a Gaussian augmentation of the mono-exponential (GAME) model.

Ciris PA, Balasubramanian M, Seethamraju RT, Tokuda J, Scalera J, Penzkofer T, Fennessy FM, Tempany-Afdhal CM, Tuncali K, Mulkern RV.

NMR Biomed. 2016 Jul;29(7):999-1009. doi: 10.1002/nbm.3556. Epub 2016 May 31.

10.

Bolus arrival time and its effect on tissue characterization with dynamic contrast-enhanced magnetic resonance imaging.

Mehrtash A, Gupta SN, Shanbhag D, Miller JV, Kapur T, Fennessy FM, Kikinis R, Fedorov A.

J Med Imaging (Bellingham). 2016 Jan;3(1):014503. doi: 10.1117/1.JMI.3.1.014503. Epub 2016 Mar 1.

11.

Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center.

Van den Abbeele AD, Krajewski KM, Tirumani SH, Fennessy FM, DiPiro PJ, Nguyen QD, Harris GJ, Jacene HA, Lefever G, Ramaiya NH.

J Am Coll Radiol. 2016 Apr;13(4):365-71. doi: 10.1016/j.jacr.2015.11.002. Epub 2016 Jan 14.

PMID:
26774886
12.

Quantitative Imaging in Cancer Clinical Trials.

Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL.

Clin Cancer Res. 2016 Jan 15;22(2):284-90. doi: 10.1158/1078-0432.CCR-14-3336. Review.

13.

Potential of minimally invasive procedures in the treatment of uterine fibroids: a focus on magnetic resonance-guided focused ultrasound therapy.

Fischer K, McDannold NJ, Tempany CM, Jolesz FA, Fennessy FM.

Int J Womens Health. 2015 Nov 13;7:901-12. doi: 10.2147/IJWH.S55564. eCollection 2015. Review.

14.

Prostate cancer discrimination in the peripheral zone with a reduced field-of-view T(2)-mapping MRI sequence.

Yamauchi FI, Penzkofer T, Fedorov A, Fennessy FM, Chu R, Maier SE, Tempany CM, Mulkern RV, Panych LP.

Magn Reson Imaging. 2015 Jun;33(5):525-30. doi: 10.1016/j.mri.2015.02.006. Epub 2015 Feb 14.

15.

Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation.

Fennessy FM, Fedorov A, Penzkofer T, Kim KW, Hirsch MS, Vangel MG, Masry P, Flood TA, Chang MC, Tempany CM, Mulkern RV, Gupta SN.

Magn Reson Imaging. 2015 Sep;33(7):886-94. doi: 10.1016/j.mri.2015.02.008. Epub 2015 Feb 14.

16.

The role of pathology correlation approach in prostate cancer index lesion detection and quantitative analysis with multiparametric MRI.

Fedorov A, Penzkofer T, Hirsch MS, Flood TA, Vangel MG, Masry P, Tempany CM, Mulkern RV, Fennessy FM.

Acad Radiol. 2015 May;22(5):548-55. doi: 10.1016/j.acra.2014.12.022. Epub 2015 Feb 13.

17.

Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor.

Howard SA, Gray KP, O'Donnell EK, Fennessy FM, Beard CJ, Sweeney CJ.

AJR Am J Roentgenol. 2014 Oct;203(4):W415-20. doi: 10.2214/AJR.13.11615.

PMID:
25247970
18.

Transperineal in-bore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study.

Penzkofer T, Tuncali K, Fedorov A, Song SE, Tokuda J, Fennessy FM, Vangel MG, Kibel AS, Mulkern RV, Wells WM, Hata N, Tempany CM.

Radiology. 2015 Jan;274(1):170-80. doi: 10.1148/radiol.14140221. Epub 2014 Sep 15.

19.

Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series.

Murciano-Goroff YR, Wolfsberger LD, Parekh A, Fennessy FM, Tuncali K, Orio PF 3rd, Niedermayr TR, Suh WW, Devlin PM, Tempany CM, Sugar EH, O'Farrell DA, Steele G, O'Leary M, Buzurovic I, Damato AL, Cormack RA, Fedorov AY, Nguyen PL.

Radiat Oncol. 2014 Sep 9;9:200. doi: 10.1186/1748-717X-9-200.

20.

MRI-guided focused ultrasound surgery for uterine fibroid treatment: a cost-effectiveness analysis.

Kong CY, Meng L, Omer ZB, Swan JS, Srouji S, Gazelle GS, Fennessy FM.

AJR Am J Roentgenol. 2014 Aug;203(2):361-71. doi: 10.2214/AJR.13.11446.

21.

Letter to cancer center directors: Progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials.

Mountz JM, Yankeelov TE, Rubin DL, Buatti JM, Erikson BJ, Fennessy FM, Gillies RJ, Huang W, Jacobs MA, Kinahan PE, Laymon CM, Linden HM, Mankoff DA, Schwartz LH, Shim H, Wahl RL.

J Clin Oncol. 2014 Jul 1;32(19):2115-6. doi: 10.1200/JCO.2014.55.8866. Epub 2014 May 27. No abstract available.

22.

Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.

Fennessy FM, McKay RR, Beard CJ, Taplin ME, Tempany CM.

Transl Oncol. 2014 Feb 1;7(1):120-9. eCollection 2014 Feb.

23.

Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results.

Hurwitz MD, Ghanouni P, Kanaev SV, Iozeffi D, Gianfelice D, Fennessy FM, Kuten A, Meyer JE, LeBlang SD, Roberts A, Choi J, Larner JM, Napoli A, Turkevich VG, Inbar Y, Tempany CM, Pfeffer RM.

J Natl Cancer Inst. 2014 Apr 23;106(5). pii: dju082. doi: 10.1093/jnci/dju082.

24.

A comparison of two methods for estimating DCE-MRI parameters via individual and cohort based AIFs in prostate cancer: a step towards practical implementation.

Fedorov A, Fluckiger J, Ayers GD, Li X, Gupta SN, Tempany C, Mulkern R, Yankeelov TE, Fennessy FM.

Magn Reson Imaging. 2014 May;32(4):321-9. doi: 10.1016/j.mri.2014.01.004. Epub 2014 Jan 21.

25.

Volumetric CT-based segmentation of NSCLC using 3D-Slicer.

Velazquez ER, Parmar C, Jermoumi M, Mak RH, van Baardwijk A, Fennessy FM, Lewis JH, De Ruysscher D, Kikinis R, Lambin P, Aerts HJ.

Sci Rep. 2013 Dec 18;3:3529. doi: 10.1038/srep03529.

26.

Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.

Galsky MD, Xie W, Nakabayashi M, Ross RW, Fennessy FM, Tempany CM, Choueiri TK, Khine K, Kantoff PW, Taplin ME, Oh WK.

Prostate Cancer Prostatic Dis. 2013 Sep;16(3):266-70. doi: 10.1038/pcan.2013.15. Epub 2013 May 28.

27.

Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer.

Hegde JV, Mulkern RV, Panych LP, Fennessy FM, Fedorov A, Maier SE, Tempany CM.

J Magn Reson Imaging. 2013 May;37(5):1035-54. doi: 10.1002/jmri.23860. Review.

28.

MR-guided focused ultrasound (MRgFUS) is effective for the distinct pattern of uterine fibroids seen in African-American women: data from phase III/IV, non-randomized, multicenter clinical trials.

Machtinger R, Fennessy FM, Stewart EA, Missmer SA, Correia KF, Tempany CM.

J Ther Ultrasound. 2013 Dec 2;1:23. doi: 10.1186/2050-5736-1-23. eCollection 2013.

29.

A Bayesian nonrigid registration method to enhance intraoperative target definition in image-guided prostate procedures through uncertainty characterization.

Pursley J, Risholm P, Fedorov A, Tuncali K, Fennessy FM, Wells WM, Tempany CM, Cormack RA.

Med Phys. 2012 Nov;39(11):6858-67. doi: 10.1118/1.4760992.

30.

Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer.

Hegde JV, Chen MH, Mulkern RV, Fennessy FM, D'Amico AV, Tempany CM.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):e101-7. doi: 10.1016/j.ijrobp.2012.08.032. Epub 2012 Oct 3.

31.

In-bore setup and software for 3T MRI-guided transperineal prostate biopsy.

Tokuda J, Tuncali K, Iordachita I, Song SE, Fedorov A, Oguro S, Lasso A, Fennessy FM, Tempany CM, Hata N.

Phys Med Biol. 2012 Sep 21;57(18):5823-40. doi: 10.1088/0031-9155/57/18/5823. Epub 2012 Sep 5.

32.

Promise and pitfalls of quantitative imaging in oncology clinical trials.

Kurland BF, Gerstner ER, Mountz JM, Schwartz LH, Ryan CW, Graham MM, Buatti JM, Fennessy FM, Eikman EA, Kumar V, Forster KM, Wahl RL, Lieberman FS.

Magn Reson Imaging. 2012 Nov;30(9):1301-12. doi: 10.1016/j.mri.2012.06.009. Epub 2012 Aug 13. Review.

33.

Practical considerations in T1 mapping of prostate for dynamic contrast enhancement pharmacokinetic analyses.

Fennessy FM, Fedorov A, Gupta SN, Schmidt EJ, Tempany CM, Mulkern RV.

Magn Reson Imaging. 2012 Nov;30(9):1224-33. doi: 10.1016/j.mri.2012.06.011. Epub 2012 Aug 13.

34.

Informatics methods to enable sharing of quantitative imaging research data.

Levy MA, Freymann JB, Kirby JS, Fedorov A, Fennessy FM, Eschrich SA, Berglund AE, Fenstermacher DA, Tan Y, Guo X, Casavant TL, Brown BJ, Braun TA, Dekker A, Roelofs E, Mountz JM, Boada F, Laymon C, Oborski M, Rubin DL.

Magn Reson Imaging. 2012 Nov;30(9):1249-56. doi: 10.1016/j.mri.2012.04.007. Epub 2012 Jul 6.

35.

Image registration for targeted MRI-guided transperineal prostate biopsy.

Fedorov A, Tuncali K, Fennessy FM, Tokuda J, Hata N, Wells WM, Kikinis R, Tempany CM.

J Magn Reson Imaging. 2012 Oct;36(4):987-92. doi: 10.1002/jmri.23688. Epub 2012 May 29.

36.

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.

Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK.

Cancer. 2012 Oct 1;118(19):4777-84. doi: 10.1002/cncr.27416. Epub 2012 Jan 26.

37.

Re: "ACR Appropriateness Criteria® on treatment of uterine leiomyomas".

Fennessy FM, Tempany CM, Jolesz FA, Stewart EA.

J Am Coll Radiol. 2011 Sep;8(9):e1-2; author reply e2-3. doi: 10.1016/j.jacr.2011.06.017. No abstract available.

PMID:
21889739
38.

Successful MRI-Guided Focused Ultrasound Uterine Fibroid Treatment Despite an Ostomy and Significant Abdominal Wall Scarring.

Machtinger R, Tempany CM, Kanan Roddy A, Fennessy FM.

ISRN Obstet Gynecol. 2011;2011:962621. doi: 10.5402/2011/962621. Epub 2010 Oct 17.

39.

Urothelial cancers of the upper urinary tract: metastatic pattern and its correlation with tumor histopathology and location.

Shinagare AB, Fennessy FM, Ramaiya NH, Jagannathan JP, Taplin ME, Van den Abbeele AD.

J Comput Assist Tomogr. 2011 Mar-Apr;35(2):217-22. doi: 10.1097/RCT.0b013e31820d7a37.

PMID:
21412093
40.

Quality-of-life assessment of fibroid treatment options and outcomes.

Fennessy FM, Kong CY, Tempany CM, Swan JS.

Radiology. 2011 Jun;259(3):785-92. doi: 10.1148/radiol.11100704. Epub 2011 Mar 1.

41.

Multiple inflammatory nodules: a differential diagnosis of new pulmonary nodules in oncology patients.

Shinagare AB, Cunto-Amesty G, Fennessy FM.

Cancer Imaging. 2011 Feb 3;10:205-8. doi: 10.1102/1470-7330.2010.0031.

42.

Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor.

Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD.

AJR Am J Roentgenol. 2011 Jan;196(1):117-22. doi: 10.2214/AJR.10.5036.

PMID:
21178055
43.

Case report. PET/CT appearance of desmoid tumour of the chest wall.

Souza FF, Fennessy FM, Yang Q, van den Abbeele AD.

Br J Radiol. 2010 Feb;83(986):e39-42. doi: 10.1259/bjr/18648939.

44.

MR imaging-guided interventions in the genitourinary tract: an evolving concept.

Fennessy FM, Tuncali K, Morrison PR, Tempany CM.

Magn Reson Imaging Clin N Am. 2010 Feb;18(1):11-28. doi: 10.1016/j.mric.2009.09.002.

45.

MRI-based thermal dosimetry and diffusion-weighted imaging of MRI-guided focused ultrasound thermal ablation of uterine fibroids.

Pilatou MC, Stewart EA, Maier SE, Fennessy FM, Hynynen K, Tempany CM, McDannold N.

J Magn Reson Imaging. 2009 Feb;29(2):404-11. doi: 10.1002/jmri.21688.

46.

Uterine leiomyomas: MR imaging-guided focused ultrasound surgery--imaging predictors of success.

Lénárd ZM, McDannold NJ, Fennessy FM, Stewart EA, Jolesz FA, Hynynen K, Tempany CM.

Radiology. 2008 Oct;249(1):187-94. doi: 10.1148/radiol.2491071600. Epub 2008 Aug 11.

47.

MR imaging-guided interventions in the genitourinary tract: an evolving concept.

Fennessy FM, Tuncali K, Morrison PR, Tempany CM.

Radiol Clin North Am. 2008 Jan;46(1):149-66, vii. doi: 10.1016/j.rcl.2008.01.004. Review.

48.

Avoiding treatment of leiomyosarcomas: the role of magnetic resonance in focused ultrasound surgery.

Samuel A, Fennessy FM, Tempany CM, Stewart EA.

Fertil Steril. 2008 Sep;90(3):850.e9-12. Epub 2007 Nov 26.

PMID:
18022163
49.

Uterine leiomyomas: MR imaging-guided focused ultrasound surgery--results of different treatment protocols.

Fennessy FM, Tempany CM, McDannold NJ, So MJ, Hesley G, Gostout B, Kim HS, Holland GA, Sarti DA, Hynynen K, Jolesz FA, Stewart EA.

Radiology. 2007 Jun;243(3):885-93. Epub 2007 Apr 19.

PMID:
17446521
50.

A review of magnetic resonance imaging-guided focused ultrasound surgery of uterine fibroids.

Fennessy FM, Tempany CM.

Top Magn Reson Imaging. 2006 Jun;17(3):173-9. Review.

PMID:
17414074

Supplemental Content

Loading ...
Support Center